These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12180844)

  • 1. The impact of regulatory policy on the development of somatic cell therapies in the United States.
    Gee AP
    Transpl Immunol; 2002 May; 9(2-4):295-300. PubMed ID: 12180844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of a quality assurance/quality control compliance program consistent with FDA regulations and policies for somatic cell and gene therapies: a four year experience.
    du Moulin GC; Pitkin Z; Shen YJ; Conti E; Stewart JK; Charles C; Hamilton D
    Cytotechnology; 1994; 15(1-3):365-72. PubMed ID: 7765951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for human somatic cell therapy and gene therapy. March 1998. Center for Biologics Evaluation and Research, Food and Drug Administration.
    Hum Gene Ther; 1998 Jul; 9(10):1513-24. PubMed ID: 9681422
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulatory issues in cellular therapies.
    Gee AP
    J Cell Biochem Suppl; 2002; 38():104-12. PubMed ID: 12046844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European approval system for advanced therapies: good news for patients and innovators alike.
    Hughes-Wilson W; Mackay D
    Regen Med; 2007 Jan; 2(1):5-6. PubMed ID: 17465768
    [No Abstract]   [Full Text] [Related]  

  • 6. [Impact of regulations on translational research in cell and gene therapy: the American experience].
    Rousseau RF; Gee AP
    Bull Cancer; 2004 Mar; 91(3):239-47. PubMed ID: 15171048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA oversight of cell therapy clinical trials.
    Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
    Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cell based therapy and the policy implications in India.
    Mukhopadhyay B; Basak SK; Ganguly NK
    J Stem Cells; 2011; 6(3):155-79. PubMed ID: 23264999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA "reinvents" human cell and tissue regulations.
    Brower V
    Nat Biotechnol; 1997 May; 15(5):411. PubMed ID: 9131612
    [No Abstract]   [Full Text] [Related]  

  • 10. Global harmonization of regulatory requirements for premarket approval of autologous cell therapies.
    Ward SM
    Food Drug Law J; 2000; 55(2):225-43. PubMed ID: 12269366
    [No Abstract]   [Full Text] [Related]  

  • 11. Unified agenda of federal regulatory and deregulatory actions--HHS. Semiannual regulatory agenda.
    Fed Regist; 1998 Nov; 63(216 Pt 2):61680-786. PubMed ID: 10187396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Requirements for long-term follow-up on efficacy and safety of advanced therapy medicinal products. Risk management and traceability].
    Klug B; Reinhardt J; Schröder C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):58-62. PubMed ID: 19949763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US gene therapy in crisis.
    Teichler Zallen D
    Trends Genet; 2000 Jun; 16(6):272-5. PubMed ID: 10827455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MQSA update.
    Odle TG
    Radiol Technol; 2003; 74(3):202-20; quiz 221-4, 227. PubMed ID: 12584968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidance for human somatic cell therapy and gene therapy.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research.
    Hum Gene Ther; 2001 Feb; 12(3):303-14. PubMed ID: 11177566
    [No Abstract]   [Full Text] [Related]  

  • 16. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access to advanced therapy medicinal products in the EU: where do we stand?
    Mahalatchimy A
    Eur J Health Law; 2011 May; 18(3):305-17. PubMed ID: 21870592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory review by the new administration: what's the impact?
    Hosp Outlook; 2001 Feb; 4(2):6, 12. PubMed ID: 11246778
    [No Abstract]   [Full Text] [Related]  

  • 19. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell transplantation and Federal regulation.
    Noguchi PD
    Cell Transplant; 1995; 4(4):411-4. PubMed ID: 7582572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.